Two major events from IHL’s psychedelic Psi-GAD clinical trial program – US FDA PIND meeting & ethics approval

Psychedelic and cannabinoid biotech company, Incannex Healthcare Limited (ASX: IHL) today brings about the two exciting updates regarding its world 1st clinical trial program - psilocybin-assisted psychotherapy for Generalised Anxiety Disorder (Psi-GAD clinical trial): the Phase 2a Psi-GAD clinical trial has been approved by MUHREC; and the pre-IND with US FDA received positive, constructive, and supportive feedback.


大麻药物开发公司Incannex Healthcare Limited (ASX: IHL) 宣布已聘请世界领先药品公司Procaps S.A. ("Procaps") 为其用于治疗阻塞性睡眠呼吸暂停 (OSA) 的大麻素组合药物IHL-42X开发和生产软凝胶胶囊,以为其正在进行的关键的开放标签临床试验做准备,并支持后续的FDA申请。